Enzyme replacement therapy for mucopolysaccharidosis VI-experience in Taiwan

Journal of Inherited Metabolic Disease

Volumn 33, Issue SUPPL. 3, 2010, Pages

  Lin, Hsiang Yu ^a,b,c   Chen, Ming Ren ^a,b   Chuang, Chih Kuang ^a,d,e   Chen, Chih Ping ^a   Lin, Dar Shong ^a,b   Chien, Yin Hsiu ^f   Ke, Yu Yuan ^g   Tsai, Fuu Jen ^h   Pan, Hui Ping ⁱ   Lin, Shio Jean ⁱ   Hwu, Wuh Liang ^f   Niu, Dau Ming ^c,j   Lee, Ni Chung ^f   Lin, Shuan Pei ^a,k  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

^b NURSING AND MANAGEMENT COLLEGE   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^e NATIONAL TAIPEI UNIVERSITY OF TECHNOLOGY   (Taiwan)

^f NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^g CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^h CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

ⁱ NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^j TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^k NATIONAL TAIPEI UNIVERSITY OF NURSING AND HEALTH SCIENCES   (Taiwan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GLYCOSAMINOGLYCAN; N ACETYLGALACTOSAMINE 4 SULFATASE; RECOMBINANT PROTEIN;

ADOLESCENT; ARTICLE; BIOMECHANICS; CHILD; CONVALESCENCE; DRUG EFFECT; ENZYME REPLACEMENT; ENZYMOLOGY; EXERCISE TOLERANCE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INFANT; JOINT CHARACTERISTICS AND FUNCTIONS; LUNG; MALE; MORQUIO SYNDROME; MULTICENTER STUDY; PATHOPHYSIOLOGY; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SHOULDER; TAIWAN; TIME; TREATMENT OUTCOME; URINE; VITAL CAPACITY; YOUNG ADULT; CLINICAL TRIAL; DRUG EFFECTS; MUCOPOLYSACCHARIDOSIS IV; TIME FACTOR;

ADOLESCENT; BIOLOGICAL MARKERS; BIOMECHANICAL PHENOMENA; CHILD; CHILD, PRESCHOOL; ENZYME REPLACEMENT THERAPY; EXERCISE TOLERANCE; FEMALE; FORCED EXPIRATORY VOLUME; GLYCOSAMINOGLYCANS; HUMANS; INFANT; LUNG; MALE; MUCOPOLYSACCHARIDOSIS IV; N-ACETYLGALACTOSAMINE-4-SULFATASE; RANGE OF MOTION, ARTICULAR; RECOMBINANT PROTEINS; RECOVERY OF FUNCTION; RETROSPECTIVE STUDIES; SHOULDER JOINT; TAIWAN; TIME FACTORS; TREATMENT OUTCOME; VITAL CAPACITY; YOUNG ADULT; BIOMARKERS;

EID: 84897919028     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-010-9212-5     Document Type: Article

References (29)

1. American Thoracic Society (1995) Standardization of spirometry, 1994 update. Am J Respir Crit Care Med 152:1107-1136
2. Auclair D, Hopwood JJ, Brooks DA, Lemontt JF, Crawley AC (2003) Replacement therapy in Mucopolysaccharidosis type VI: advantages of early onset of therapy. Mol Genet Metab 78:163-174
3. Chen W, Chang MH (2010) New growth charts for Taiwanese children and adolescents based onWorld Health Organization standards and health-related physical fitness. Pediatr Neonatol 51:69-79
4. Chuang CK, Lin SP (2007) Neurochemical changes and therapeutical approaches in mucopolysaccharidoses. In: Surendran S, Aschner M, Bhatnagar M (eds) Neurochemistry of metabolic diseases-lysosomal storage diseases, phenylketouria and Canavan disease. Transworld Research Network, Kerala, pp 1-20
5. Chuang CK, Lin SP, Chung SF (2001) Diagnostic screening for mucopolysaccharidoses by the dimethylmethylene blue method and two dimensional electrophoresis. Zhonghua Yi Xue Za Zhi (Taipei) 64:15-22
6. CrawleyAC, NiedzielskiKH, Isaac EL,Davey RC, Byers S, Hopwood JJ (1997) Enzyme replacement therapy from birth in a feline model of mucopolysaccharidosis type VI. J Clin Invest 99:651-662
7. Fries JF (1991) The hierarchy of quality-of-life assessment, the Health Assessment Questionnaire (HAQ), and issues mandating development of a toxicity index. Control Clin Trials 12(4 Suppl):106S-117S
8. Giugliani R, Harmatz P, Wraith JE (2007) Management guidelines for mucopolysaccharidosis VI. Pediatrics 120:405-418
9. Guimarães Mdo C, de Farias SM, Costa AM, de Amorim RF (2010) Maroteaux-Lamy syndrome: orofacial features after treatment by bone marrow transplant. Oral Health Prev Dent 8:139-142
10. Harmatz P, Whitley CB, Waber L (2004) Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr 144:574-580
11. Harmatz P, Ketteridge D, Giugliani R et al. (2005) Direct comparison of measures of endurance, mobility, and joint function during enzymereplacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-Acetylgalactosamine 4-sulfatase. Pediatrics 115:e681-e689
12. Harmatz P, Giugliani R, Schwartz I et al. (2006) Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-Acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr 148:533-539
13. Harmatz P, Giugliani R, Schwartz IV et al. (2008) Long-term followup of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: final results of three clinical studies of recombinant human N-Acetylgalactosamine 4-sulfatase. Mol Genet Metab 94:469-475
14. Harmatz P, Yu ZF, Giugliani R (2010) Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human Nacetylgalactosamine 4-sulfatase. J Inherit Metab Dis 33:51-60
15. Herskhovitz E, Young E, Rainer J et al. (1999) Bone marrow transplantation for Maroteaux-Lamy syndrome (MPS VI): longterm follow-up. J Inherit Metab Dis 22:50-62
16. Krivit W, Pierpont ME, Ayaz K et al. (1984) Bone-marrow transplantation in the Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI). Biochemical and clinical status 24 months after transplantation. N Engl J Med 311:1606-1611
17. Lee V, Li CK, Shing MM et al. (2000) Umbilical cord blood transplantation for Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI). Bone Marrow Transplant 26:455-458
18. Lin WD, Lin SP, Wang CH et al. (2008) Genetic analysis of mucopolysaccharidosis type VI in Taiwanese patients. Clin Chim Acta 394:89-93
19. Lin HY, Lin SP, Chuang CK et al. (2009) Incidence of the mucopolysaccharidoses in Taiwan, 1984-2004. Am J Med Genet A 149A:960-964
20. Lin HY, Chen MR, Lin CC et al. (2010) Polysomnographic characteristics in patients with mucopolysaccharidoses. Pediatr Pulmonol 2010 Aug 17. [Epub ahead of print]
21. McGill JJ, Inwood AC, Coman DJ et al. (2010) Enzyme replacement therapy for mucopolysaccharidosis VI from 8 weeks of age-A sibling control study. Clin Genet 77:492-498
22. Neufeld EF, Muenzer J (2001) The mucoplysaccharidoses. In: Scriver CR, Beaudet al., Sly WS, Valle D, Childs B, Kinzler KW, Vogelstein B (eds) The metabolic and molecular bases of inherited disease, 8th edn. McGraw-Hill, New York, pp 3421-3452
23. Ramey DR, Raynauld JP, Fries JF (1992) The health assessment questionnaire 1992: status and review. Arthritis Care Res 5:119-129
24. Scarpa M, Barone R, Fiumara A et al. (2009) Mucopolysaccharidosis VI: the Italian experience. Eur J Pediatr 168:1203-1206
25. Singh G, Athreya BH, Fries JF, Goldsmith DP (1994) Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum 37:1761-1769
26. Swiedler SJ, Beck M, Bajbouj M et al. (2005) Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). Am J Med Genet A 134A:144-150
27. Uçakhan OO, Brodie SE, Desnick R, Willner J, Asbell PA (2001) Long-term follow-up of corneal graft survival following bone marrow transplantation in the Maroteaux-Lamy syndrome. CLAO J 27:234-237
28. Wang CC, Hwu WL, Lin KH (2008) Long-term follow-up of a girl with Maroteaux-Lamy syndrome after bone marrow transplantation. World J Pediatr 4:152-154
29. Wraith JE, Clarke LA, Beck M et al. (2004) Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, doubleblinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr 144:581-588